Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial
165
PFE: Pfizer Inc. 2021-08-30 06:45:00 Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis